Reversible encephalopathy and axonal neuropathy in Parkinson's disease during duodopa therapy.
Davide
D
Manca
Giovanni
G
Cossu
Daniela
D
Murgia
Andrea
A
Molari
Paola
P
Ferrigno
Emanuele
E
Marcia
Maurizio
M
Melis
D000368:Aged; D000978:Antiparkinson Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D002396:Catechols / Q000009:adverse effects* / Q000627:therapeutic use*; D004660:Encephalitis / Q000139:chemically induced*; D005260:Female; D006801:Humans; D007980:Levodopa / Q000009:adverse effects / Q000627:therapeutic use; D009570:Nitriles / Q000009:adverse effects* / Q000627:therapeutic use*; D010300:Parkinson Disease / Q000188:drug therapy*; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced*
D000978:Antiparkinson Agents; D002396:Catechols; D009570:Nitriles; D007980:Levodopa; C071192:entacapone